At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
At the recent 12th IDF-WPR Congress and 10th AASD Scientific Meeting held at Kuala Lumpur Convention Centre, the importance of glycaemic control and the practical management of type 2 diabetes mellitus (T2DM) were highlighted by two international speakers, Dr Sanjay Kalra from India and Professor Jean Claude Mbanya from Cameroon.
At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.
At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.
Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 20181011035429
The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.
At the recent ‘Reinforced for the Glycaemic Challenge’ symposium held at Shangri-la Hotel, Kuala Lumpur, Associate Professor Dr Alexander Tan, Professor Dr Chee Kok Han and Dr Chan Siew Pheng shared their insights into the importance of achieving glycaemic control in patients with type 2 diabetes mellitus (T2DM), while simultaneously providing them with cardiovascular protection.
At the Diabetes Asia 2016 Conference organized by the National Diabetes Institute, Professor Jean Claude Mbanya presented the case for why gliclazide modified release (MR; Diamicron® MR, Servier) should be the treatment of choice for early and aggressive control of type 2 diabetes (T2D).